Immunohistochemical quantification of substance P in spinal dorsal horns of patients with multiple system atrophy

Naoyuki Tomokane, Tetsuyuki Kitamoto, Jun Tateishi, Yuji Sato

Abstract

Using a computer-assisted image analyser, an immunohistochemical quantification method of substance P-like immunoreactivity (SPLI) in laminae I + II of spinal dorsal horn was established and applied to 13 patients with multiple system atrophy (MSA) with no disturbance of pain sensation, including olivoponto-cerebellar atrophy and striatonigral degeneration, and 13 neurologically normal controls. To investigate whether alteration of SPLI is related to an autonomic disorder, myelinated fibre counts of the fourth thoracic ventral roots were performed. Eleven of 13 MSA patients showed a significant decrease in small and large myelinated fibres, and were diagnosed with definite Shy-Drager syndrome (SDS), with the exception of two who had no apparent history of autonomic dysfunction. SPLIs in laminae I + II in 10 of these 11 patients, when adjusted for age, were significantly decreased at both levels of the fourth thoracic and third lumbar spinal segments. The results suggest the disorder of SP-containing synapses of primary afferent neurons and/or those of interneurons in SDS.

The neuropeptide substance P (SP) has been suggested as a nociceptive neurotransmitter^{1,2} or a neuromodulator^{3,4} of primary afferent neurons. A marked depletion of SP-like immunoreactivity (SPLI) in the superficial laminae of the dorsal horn was reported in several conditions: dorsal rhizotomy,⁵ capsaicin treatment^{6,7} and peripheral nerve lesions.^{8,9} Most of the SP in the superficial dorsal horn may be contained in the central terminals of unmyelinated C-fibres of small diameter cells in the dorsal root ganglia. Nociceptive information is relayed to both lamina I and the outer layer of lamina II,^{10,11} and to a lesser extent to the inner layer of lamina II.¹¹ This localisation pattern of SP has been supported by a number of immunohistochemical studies showing the strongest immunoreactions in lamina I and dorsal parts of lamina II.^{1,12,13} On the grounds that SP antigenicity can be retained in formaldehyde-fixed and paraffin-embedded specimens for many years,¹⁴ a quantitative immunohistochemistry for SP in the laminae I + II can be available for evaluation of synapses containing SP of both intrinsic and extrinsic origin.

Shy-Drager syndrome (SDS)¹⁵ is character-

ised by the autonomic failure, such as orthostatic hypotension, urinary incontinence, inability to perspire, and sexual impotence, attributable to loss of preganglionic cells in the intermediolateral nuclei (IML).¹⁶ Since this syndrome frequently shows widespread neuronal degeneration in the striatonigral system, locus ceruleus, pontine nuclei, inferior olive and cerebellar cortex,¹⁷ it is therefore classified as multiple system atrophy (MSA).¹⁸ Several morphometric studies on thoracic ventral roots of the patients with SDS have shown that small myelinated fibres decrease significantly in number as an explanation of autonomic dysfunction.^{19,20} Although unmyelinated fibres compose a large part of the autonomic pathway, only comparatively few studies have been done concerning the affection of peripheral unmyelinated fibres in SDS.^{21,22}

In this study, patients with MSA were first divided into two classes either with or without autonomic disorders by their clinical and pathological findings, as well as morphometric features of the thoracic ventral roots. Secondly, after evaluating the effects of necropsy delay on SP immunostain, an optimal condition for the SP immunohistochemistry and a quantification method for image analysis were established and then applied to those patients and controls.

Materials and methods

Patients

Necropsies were carried out on 13 patients with MSA, all with olivoponto-cerebellar atrophy (OPCA), 10 with striato-nigral degeneration (SND) (table 1), and 13 age matched controls without neurological disorder (table 2). There was no definite loss of pain sensation in any of the patients. Maximal intervals between death and beginning of necropsy were 11 and 14 hours. After a maximal length of 24 or 25 days fixation by 10% neutralised formalin in each group, the sixth cervical (C6), fourth thoracic (T4) and third lumbar (L3) segments of the spinal cord were excised, embedded in paraffin and cut into 7 µm transverse sections. Serial sections were processed for HE, Klüver-Barrera's (KB) stains and SP immunohistochemistry.

The sampling and processing of morphology of the T4 ventral roots were performed according to the Low and Dyck method.²³ The transverse fascicular area and the diameter distribution of myelinated fibres per root were measured in photographs magnified to × 100

Department of Neuropathology, Neurological Institute and Department of Orthopedics,* Faculty of Medicine, Kyushu University, Fukuoka, Japan

N Tomokane*
T Kitamoto
J Tateishi

Laboratory of Neuropathology, Hizen National Mental Hospital, Kanzaki, Saga, Japan
Y Sato

Correspondence to: N Tomokane, Department of Neuropathology, Neurological Institute, Faculty of Medicine, Kyushu University 60, Fukuoka 812, Japan

Received 18 June 1990.

Accepted 1 September 1990

Table 1 Patients with multiple system atrophy

Case	Age	Sex	PI	Fix L	Duration		Autonomic sign			Pathology	
					FT	AD	OH	VRD	AH	OPCA	SND
M 1	44	F	7	23	3	1, 6	—	+	ND	+	+
M 2	51	F	10	14	9	4, 0	+	+	ND	+	+
M 3	52	F	4.5	18	13		ND	+	ND	+	+
M 4	57	M	5.5	20	4	3, 7	+	+	ND	+	— ^a
M 5	59	F	4	21	8	6, 2	+	+	+	+	+
M 6	61	M	8	24	5	5, 0	+	+	+	+	+
M 7	61	F	11	18	7		—	—	—	+	—
M 8	62	F	3	19	6	3, 9	+	+	ND	+	+
M 9	63	F	3	10	7		—	—	—	+	—
M10	64	M	7.5	14	6	4, 0	+	+	+	+	+
M11	68	F	9	19	8	5, 10	+	+	ND	+	+
M12	72	M	10	21	5	2, 0	ND	+	+	+	+
M13	73	F	5	ND	6	5, 6	ND	+	+	+	+
Mean	60.3		6.7	18.4	6.9	4, 2					

PI: postmortem interval (hours); Fix L: fixation length (days); FT: full term (years); AD: duration of autonomic dysfunction (years, months); OH: orthostatic hypotension; VRD: vesicorectal disturbance including dysuria, urinary incontinence and constipation; AH: anhidrosis; Pathology: complicated pathological diagnosis; OPCA: olivo-ponto-cerebellar atrophy; SND: striato-nigral degeneration; ND: not described in necropsy record; a: mild gliosis without neuronal loss.

Table 2 Age-matched controls

Case	Age	Sex	Cause of death	PI	Fix L
C 1	42	M	Acute renal failure	5.5	21
C 2	49	F	Cardiac	3	16
C 3	52	M	Pulmonary bleeding	2	16
C 4	53	F	Head trauma	12	18
C 5	58	M	Sudden death	2.5	19
C 6	61	M	Subarachnoid haemorrhage	10	16
C 7	65	F	Subarachnoid haemorrhage	14	17
C 8	69	F	Suicide	4	25
C 9	71	M	Acute abdomen	5	24
C10	71	F	Subarachnoid haemorrhage	3	22
C11	73	M	Acute renal failure	2	18
C12	78	F	Head trauma	4.5	20
C13	82	F	Cardiac	13.5	17
Mean	63.4			6.2	19.2

PI: postmortem interval (hours); Fix L: fixation length (days).

and $\times 1000$, respectively. According to the diameter distributions in the control study, the division point between large and small myelinated fibres was determined at $6.16 \mu\text{m}$.

Adult rats (Sprague-Dawley; 230–250 g; $n = 47$) were decapitated under deep anaesthesia with diethyl ether and were kept at 4°C . At six different intervals (0, 2, 4, 8, 16 and 24 hours) the lumbar spinal cord segments were excised and immediately immersed in 10% neutralised formalin for two days at room temperature. The fifth lumbar segments were dissected and processed in the same manner as the human materials.

Polyclonal anti-SP antibody was raised in a New Zealand white rabbit against synthetic SP (Peptide Institute, Osaka, Japan), which was conjugated to bovine serum albumin (BSA) with carbodiimide as a coupling agent according to Chopra.²⁴ An anti-SP titre was raised to 1:12 800 dilution against 70 ng synthetic SP by dot blotting immunoassay (Promega Biotec, Madison). Antiserum specificity was tested with both preabsorbed serum and affinity-purified antibody. Immunostaining was abolished by the preabsorption of the antibody with synthetic SP ($5 \mu\text{g}/1 \text{ ml}$ SP antiserum). Affinity-purified antibody, which was prepared from the whole SP antiserum by the method of Talian *et al.*,²⁵ differentiated the SP in the dorsal horn of the spinal cord less strongly than the whole SP antiserum while distribution of the immunostained vesicles was similar to each other. Control sections stained with pre-immune serum showed no positive stain.

Immunostaining was performed using the whole SP antiserum.

After removing the paraffin, the tissue sections were pretreated with 0.3% H_2O_2 for 30 minutes to reduce non-specific staining by endogenous peroxidases. The unlabelled antibodies biotin-streptavidin method (Stravigen, BioGenix Laboratories, Dublin, CA) was applied. After washing with PB (0.1M phosphate, 0.5M NaCl, pH 7.3), the sections were incubated for two days at 4°C with diluted anti-SP containing 0.2% Triton X-100. After washing with PB, the tissue sections were exposed with biotinylated anti-rabbit IgG antibodies and streptavidin-horseradish peroxidase complex for three hours each, at room temperature. Diaminobenzidine tetrahydrochloride (DAB) containing H_2O_2 was used to develop the colour.

To obtain a high contrast between SP-specific immunoreactive products and the surrounding background in light microscopic image analysis, optimal immunohistochemical conditions were examined according to the method proposed by Gross.²⁶ As major effective variables, antibody dilution (1/8000–1/250), DAB concentration (0.002–0.05%), H_2O_2 concentration (0.0005–0.05%) and reaction time in DAB (1–10 min) were altered independently. Consecutive serial sections of the L3 segment of a control (C11) was used for this purpose. To avoid any misinterpretation during image analysis, no counterstain was done.

A computer-assisted image analyser (IBAS II, Kontron) was used for quantification of SP-specific immunoreactive products. After appropriately setting the detection threshold, the total area occupied by these products (immunostained area) in the whole area of laminae I + II (reference area) was extracted from the background. The percentage of the immunostained area versus the reference area was calculated (%Ia) and those of the bilateral dorsal horn were averaged. Because the borderline between lamina II and III could not be directly ensured on the immunohistochemical preparation without counter stain, the reference area was determined from its neighbouring KB preparation as follows: a digitised image of the dorsal horn, which was obtained from the KB preparation at each level of the spinal segments through a videomicro-

Figure 1 Schematic illustrations in set of reference area at the level of the L3 cord segment. Reference area necessary to immunohistochemical quantification (A) was obtained by transforming the contour of laminae I + II circumscribed by the top of arrow heads in the neighbouring section with KB stain (B). The areas occupied by large vessels and fibre bundles were excluded from the object. Bars = 300 μ m.

Figure 2 Numbers of small (A) and large (B) myelinated fibres per T4 ventral root of controls (●), SDS (□) patients and other patients (△).

Figure 3 Transverse sections and diameter distributions of the T4 ventral roots of a control (C4) (A, C) and a SDS patient (M4) (B, D). Bars = 20 μ m.

Figure 4 Effect of various postmortem intervals on SPLI in rats.

scope hardware, was stored in one image memory (KB-image memory) at 120 $\times$ magnification. The image of the identical site of SP immunohistochemical preparation was stored in another image memory (SP-image memory) at the same magnification. On the TV image on-line with KB-image memory, the contour of laminae I + II was drawn as an overlay image

Table 3 Numbers of myelinated fibres of the T4 ventral root and SPLI in laminae I+II

	Number of myelinated fibres		SPLI (%Ia)		
	SMF	LMF	C6	T4	L3
C 1	5183	1720	5.17	4.47	4.89
C 2	6154	1834	7.90	3.81	4.52
C 3	5649	1547	5.41	4.06	6.73
C 4	4421	1426	6.45	5.14	6.14
C 5	5213	1569	3.52	3.27	3.75
C 6	4207	1505	4.08	5.45	5.89
C 7	3917	1432	3.91	4.31	3.04
C 8	4416	1610	4.22	2.16	3.90
C 9	5815	1516	2.26	2.73	2.39
C10	3986	1205	1.86	2.49	2.04
C11	3618	1248	2.14	1.52	5.08
C12	4021	1293	2.10	2.21	2.41
C13	4163	1488	1.47	0.98	1.76
Mean (SD)	4674 (794)	1492 (171)	3.88 (1.88)	3.23 (1.34)	4.04 (1.59)
M 1	1627*	490*	0.97*	0.24*	0.48*
M 2	984*	583*	2.84*	0.46*	0.86*
M 3	2103*	1082*	4.18	3.01	3.21*
M 4	1983*	725*	3.74	1.21*	2.19*
M 5	528*	279*	0.79*	1.52*	1.17*
M 6	1763*	694*	0.24*	0.59*	0.62*
M 7	4826	1542	2.08	4.61	3.68
M 8	1537*	429*	0.74*	0.11*	0.76*
M 9	4110	1250	4.63	2.83	5.54
M10	1285*	1071*	2.27	1.56*	2.39*
M11	2010*	754*	3.62	0.18*	2.30
M12	1951*	793*	5.31	0.46*	0.40*
M13	1748*	671*	1.52	0.07*	0.58*
Mean (SD)	2035 (1130)	797 (339)	2.34 ^S (1.59 ^S)	0.68 ^S (0.56 ^S)	1.25 ^S (0.76 ^S)

Data on the T4 ventral root are expressed in number per root. SMF = small myelinated fibres; LMF = large myelinated fibres.

*Statistically significant ($p < 0.05$); S: Mean (SD) of SDS patients.

Figure 5 Effects of SP immunohistochemical parameters. A: antiserum dilution. SP specific reaction deposits reached maximal level at 1/2000 or 1/1000. Below 1/500, anti-SP showed a rapid increase with non-specific background staining. B: DAB concentration. DAB concentration was increased from 0.002 to 0.05% by holding H_2O_2 concentration constant at either 0.003 or 0.009%. With 0.003% H_2O_2 , the specific staining was maximal at 0.02% DAB. Beyond the 0.02% DAB, this H_2O_2 concentration was too low to allow an enzymatic reaction. In the presence of 0.009% H_2O_2 , at 0.01 to 0.05% DAB, the specific staining was maximal but not saturated. C: H_2O_2 concentration. H_2O_2 concentration was altered while DAB concentration was held constant at two different levels. With 0.01% DAB, the specific staining showed a linear increase to reach a maximum at 0.003 to 0.01% H_2O_2 . In more than 0.03% H_2O_2 , the area increased in a rapidly accelerating fashion due to the measurement of non-specific background feature. D: reaction time in DAB. Over the first phase, anti-SP 1/2000 have a rapid increase in detected specific reaction products. After a short plateau phase which starts at three minutes and ends at five minutes, the immunostained area increased rapidly due to non-specific staining. A: DAB = 0.01%, H_2O_2 = 0.003%, reaction time = 4 minutes, B, C: antibody dilution = 1/2000, reaction time = 4 minutes D: antibody dilution = 1/2000, DAB = 0.01%, H_2O_2 = 0.003%.

(fig 1). According to Rexed,²⁷ the nerve cells of lamina II in a cat were either round or more often slightly elongated and the majority were 5–10 $\times$ 5–10 μ m in size. Those of lamina III were more varied in size with the largest cell reaching 15 $\times$ 18 μ m around. In KB preparation, the increasing number of fibres in lamina III contributed to a darker appearance as a whole than lamina II. This overlay image was subsequently transferred to the SP-image memory to fit the reference area. The executive programme with the above serial procedures was set up by referring to the second edition.

Results were expressed as the means (SD). Correlations were assessed by Pearson's product moment correlation test. The difference in number of myelinated fibres between the patients and controls was analysed by the Student's *t* test. The difference of SPLI (%Ia) was tested by a two-way analysis of variance (two-way ANOVA). The data were considered to be statistically significant at $p < 0.05$.

Results

In the controls, the number (per root) of small myelinated fibres (SMF) ranged from 3618 to 6154 [4674 (794)] while that of large myelinated fibres (LMF) ranged from 1205 to 1834 [1492 (171)] (table 3). Both SMF and LMF showed a significant decrease in the number with increasing age (SMF: $p < 0.05$; $R = -0.63$; $Y = 7257-40.8X$, LMF: $p < 0.05$; $R = -0.66$; $Y = 2109-9.7X$) (fig 2).

Of 13 MSA patients, 11 showed a significant decrease in the number of both SMF ($p < 0.01$) and LMF ($p < 0.01$). The decrease was more prominent in SMF than in LMF (figs 2, 3). The variation in the number among all patients was from 528 to 4826 [2035 (1130)] in SMF and from 279 to 1542 [797 (339)] in LMF (table 3). Because two (M1, M3) of these 11 patients did not show any definite autonomic failure (M1: no orthostatic hypotension, M3: vesicorectal disturbance is not specific to autonomic sign), we diagnosed the remaining nine patients as definite SDS. Two cases without any decrease in the number of SMF (M7, M9) showed no autonomic dysfunction.

SPLI in the rat spinal cord was well preserved up to at least 24 hours (fig 4). Although SPLI showed a tendency to increase slightly with time, there were no significant differences between each interval. SP-like immunoreactive products of superficial dorsal horn in rats were smaller in shape and more homogeneous than in humans.

Alterations of SPLI dependent on parametric value were shown in fig 5. As expected from the observations, anti-SP 1/2000, 0.01% DAB, 0.003% H_2O_2 and a reaction for 4 minutes are optimal values for the image analysis on the SP immunohistochemical preparations.

Figure 6 showed representative SP immunostaining of the same cases (C4, M4) as in fig 2. In the control, SP immunolabelling was seen in abundance in lamina I and the dorsal parts of lamina II(A), and showed various appearances in shape, that is, fine granular, vesicular and linear varicositous (C). In the

Figure 6 Representative SP immunostaining and its details at higher magnification in the superficial dorsal horn. A, C: a control (C4), B, D: a patient (M4). Bars for A, B = 200 μ m, bars for C, D = 50 μ m.

Figure 7 Immunostained area (%) of controls (●), SDS patients (□) and other patients (△) at the level of the C6 (A), T4 (B) and L3 (C) spinal segments.

patient, SP-positive products were severely depleted (B, D).

As shown in table 3, the controls showed wide variations of SPLI (%Ia) at three different levels of spinal cord. There were significant reductions in SPLI with increasing age at all three levels (C6: $p < 0.05$; $R = -0.86$; $Y = 12.68 - 0.14X$, T4: $p < 0.05$; $R = -0.78$; $Y = 8.98 - 0.090X$, L3: $p < 0.05$; $R = -0.69$; $Y = 10.12 - 0.10X$) (fig 7). The slopes were not significantly different between the three levels. SPLI showed no significant correlation with sex, postmortem interval and fixation length.

In the patients with SDS, SPLIs (%Ia) were also varied. The range of %Ia in SDS patients overlapped with those of the controls for the most part at the C6 level, and for a lesser part at the T4 and L3 level. But when adjusted for age (two way ANOVA), SPLIs in all SDS patients and one other patient (M1), with a significant decrease of myelinated fibres, were significantly decreased at the T4 ($p < 0.05$) and L3 ($p < 0.05$) levels except for one (M11) at the L level (fig 7). SPLI of SDS patients did not correlate statistically with the duration either of the disease or of the autonomic dysfunction.

Discussion

We performed the morphometric study to diagnose definite SDS patients. It is generally assumed that small and large myelinated fibre counts in the thoracic ventral root are simple and reliable methods to evaluate the loss of preganglionic autonomic neurons in IML, and alpha and gamma motor neurons in the ventral horn, respectively.

SPLI on the tissue section of autopsied material alters depending on either the degradation of SP itself before fixation or autolysis of the tissue which influences the immobilisation of SP by fixatives. SP in the brain was stable for at least 72 hours after death at room temperature in a biochemical study using a radioimmunoassay technique.²⁸

Degradation of SP is not considered in our cases with postmortem intervals of shorter than 16 hours. The degree of autolysis is different for each material depending on postmortem handling, especially necropsy delay, even if the material is stored in a refrigerator at a constant temperature. The effects therefore of necropsy delay on SP immunostain were examined on rat spinal cords under similar postmortem condi-

tions as humans and good preservation of SPLI up to 24 hours was confirmed. Once optimal immunohistochemical conditions were established, it was possible to compare the intensity of SPLI between each autopsied material.

SP quantitative data on the controls in this study confirmed the age-related decrease of SPLI in the superficial dorsal horn of humans. In view of the age-related decrease in the number of nerve cells of the first sacral ganglia,²⁹ this decrease of SPLI may be due to an age-related decrease in the number of SP-nerve primary afferent neurons rather than the decrease of SP content per neuron. Emson²⁸ described the content of SP in normal human brains as not significantly affected by age. This disparity is probably due to the difference of the regions studied.

Our study is the first immunohistochemical report demonstrating the decrease of SP in the superficial dorsal horn of SDS patients, which were definitely diagnosed with the morphometry of spinal ventral roots. This finding agrees with a study by Anand *et al*,³⁰ who revealed a marked depletion of SP in the spinal dorsal horn of four MSA patients by radioimmunoassay. The pain sensation of our patients, however, was almost spared entirely as in previous reports.^{15,18,19} The most likely interpretation of the results is that the loss of SP is not sufficient to affect nociception in a detectable manner. We also counted the number of myelinated fibres in the dorsal roots, but there was no significant decrease in number in SDS patients (not shown). Unmyelinated C-fibre cannot be discriminated by this method. Another plausible explanation is that the decrease of SP immunostaining in the dorsal horn is caused by the loss of non-nociceptive SP-containing visceral afferents. SP is also known to occur in interneurons of the superficial dorsal horn.² Moreover, some A delta sensory fibres contain SP.⁶ The ratio of SP content in these three populations has not been fully examined. We also performed a similar quantitative study about calcitonin-gene related peptide (CGRP), a neuropeptide co-localising with SP in neurons of dorsal root ganglia,³¹ but a decrease of CGRP was not detected in these SDS patients. The decreased concentration of SP in the cerebrospinal fluid of SDS patients may reflect the disorder of SP-containing primary sensory and/or intraspinal neurons.³² Further study will be needed to distinguish between these alternatives.

As for SP in the primary sensory neurons, it is of particular interest that SP immunoreactive fibres of a sensory nature pass through the sympathetic ganglion with SPLI varicose network surrounding postganglionic neurons³³⁻³⁶ and SP plays a transmitter role in the sympathetic ganglion.³⁷ These suggest an interaction between the autonomic disorder and the depletion of SP in primary sensory neurons of SDS patients.

This study has shown that a quantitative immunohistochemical evaluation of SPLI can be applied to human material at necropsy and SPLIs are considerably depleted in the superficial dorsal horn of the patients with SDS.

We thank Dr Akazawa and Professor Y Nose, Department of Medical Informatics, Kyushu University Hospital, for the statistical treatment of the data; K Hatanaka and M Yoneda for excellent technical assistance; and B T Quinn for his comments on the manuscript. We acknowledge the assistance of Carl Zeiss Corporation, Japan, for help with the computer-assisted image analyser.

- Cuello AC. Substance P: naturally occurring transmitter in human spinal cord. *Lancet* 1976;13:1054-6.
- Hökfelt T, Ljungdahl A, Terenius L, Elde R, Nilsson G. Immunohistochemical analysis of peptide pathways possibly related to pain and analgesia: enkephalin and substance P. *Proc Natl Acad Sci USA* 1977;74:3081-5.
- Frederickson RCA, Burgis V, Harrell CE, Edwards JD. Dual actions of substance P on nociception: Possible role of endogenous opioids. *Science* 1978;199:1359-62.
- Oehme P, Hilse H, Morgenstern E, Göres E. Substance P: Does it produce analgesia or hyperalgesia? *Science* 1980;208:305-7.
- Takahashi T, Otsuka M. Regional distribution of substance P in the spinal cord and nerve roots of the cat and the effect of dorsal root section. *Brain Res* 1975;87:1-11.
- Jessell TM, Iversen LL, Cuello AC. Capsaicin-induced depletion of substance P from primary sensory neurons. *Brain Res* 1978;152:183-8.
- Jansco G, Hökfelt T, Lundberg JM, *et al*. Immunohistochemical studies on the effect of capsaicin on spinal and medullary peptide and monoamine neurons using antisera to substance P, gastrin/CCK, somatostatin, VIP, enkephalin, neurotensin and 5-hydroxytryptamine. *J Neurocytol* 1981;10:963-80.
- Jessell TM, Tsunoo A, Kanazawa I, Otsuka M. Substance P depletion in the dorsal horn of rat spinal cord after section of the peripheral process of primary sensory neurons. *Brain Res* 1979;168:247-59.
- Di Giulio AM, Mantegazza P, Dona M, Gorio A. Peripheral nerve lesions cause simultaneous alterations of substance P and enkephalin levels in the spinal cord. *Brain Res* 1985;342:405-8.
- Light AR, Trevino DL, Perl ER. Morphological features of functionally defined neurons in the marginal zone and substantia gelatinosa of the spinal dorsal horn. *J Comp Neurol* 1979;186:151-72.
- Sugiura Y, Lee CL, Perl ER. Central projections of identified, unmyelinated (C) afferent fibers innervating mammalian skin. *Science* 1986;234:358-61.
- Baker RP, Vaughn JE, Slemmon JR, Salvaterra PM, Roberts E, Leeman SE. The origin, distribution and synaptic relationship of substance P axons in rat spinal cord. *J Comp Neurol* 1979;184:331-52.
- Chan-Palay V, Palay SL. Immunocytochemical identification of substance P cells and their processes in rat sensory ganglia and their terminals in the spinal cord: Light microscopic studies. *Proc Natl Acad Sci USA* 1977;74:3597-601.
- Pearson J, Brandeis L, Cuello AC. Depletion of substance P-containing axons in substantia gelatinosa of patients with diminished pain sensitivity. *Nature* 1982;295:61-3.
- Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension. *Archiv Neurol* 1960;2:511-27.
- Johnson RH, Lee GJ, Oppenheimer DR, Spalding JMK. Autonomic failure with orthostatic hypotension due to intermediolateral column degeneration. *Q J Med* 1966;35:276-92.
- Fichefet JP, Sternon JE, Franken L, Domanet JC, Vanderhaeghen JJ. Étude anatomo-clinique d'un cas d'hypotension orthostatique "idiopathique". *Acta Cardiol* 1965;20:332-48.
- Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1969;32:28-34.
- Low PA, Thomas JE, Dyck PJ. The splanchnic autonomic outflow in Shy-Drager syndrome and idiopathic orthostatic hypotension. *Ann Neurol* 1978;4:511-4.
- Sobue G, Hashizume Y, Ohya M, Takahashi A. Shy-Drager syndrome: neuronal loss depends on size, function, and topography in ventral spinal outflow. *Neurology* 1986;36:404-7.
- Galassi G, Nemni R, Baraldi A, Gibertoni M, Colombo A. Peripheral neuropathy in multiple system atrophy with autonomic failure. *Neurology* 1982;32:1116-21.
- Tohgi H, Tabuchi M, Tomonaga M, Izumiyama N. Selective loss of small myelinated and unmyelinated fibers in Shy-Drager syndrome. *Acta Neuropathol (Berl)* 1982;57:282-6.
- Low PA, Dyck PJ. Splanchnic preganglionic neurons in man: II. Morphometry of myelinated fibers of T₁ ventral spinal root. *Acta Neuropathol (Berl)* 1977;40:219-25.
- Chopra IJ. A radioimmunoassay of measurement of 3,3',5'-triiodothyronine (reverse T₃). *J Clin Invest* 1974;54:583-92.
- Talian JC, Olmsted JB, Goldman RD. A rapid procedure for preparing fluorescein-labeled specific antibody from whole antiserum: Its use in analyzing cytoskeletal architecture. *J Cell Biol* 1983;97:1297-82.
- Gross DS, Rothfeld JM. Quantitative immunocytochemistry of hypothalamic and pituitary hormones. *J Histochem Cytochem* 1985;33:11-20.
- Rexed B. The cytoarchitectonic organization of the spinal cord in the cat. *J Comp Neurol* 1952;96:415-95.
- Emson PC. Neuropeptides and the pathology of Huntington's disease. *Prog Brain Res* 1986;66:91-105.

- 29 Gardner E. Decrease in human neurons with age. *Anat Rec* 1940;77:529–36.
- 30 Anand P, Bannister R, McGregor GP, Ghatei MA, Mulderry PK, Bloom SR. Marked depletion of dorsal spinal cord substance P and calcitonin gene-related peptide with intact skin flare responses in multiple system atrophy. *J Neurol Neurosurg Psychiatry* 1988;51:192–6.
- 31 Gibbins IL, Furness JB, Costa M, MacIntyre I, Hillyard CJ, Girgis S. Co-localization of calcitonin gene-related peptide-like immunoreactivity with substance P in cutaneous, vascular and visceral sensory neurons of guinea pigs. *Neurosci Lett* 1985;57:125–30.
- 32 Nutt JG, Mroz EA, Leeman SE, Williams AC, Engel WK, Chase TN. Substance P in human cerebrospinal fluid: reductions in peripheral neuropathy and autonomic dysfunction. *Neurology* 1980;30:1280–5.
- 33 Gamse R, Wax A, Zigmond RE, Leeman SE. Immunoreactive substance P in sympathetic ganglia: Distribution and sensitivity towards capsaicin. *Neuroscience* 1981;6:437–41.
- 34 Helen P, Panula P, Yang HYT, Hervones A, Rapoport SI. Location of substance P-, bombesin-, gastrin-releasing peptide, [Met⁵]enkephalin- and [Met⁵]enkephalin-Arg⁶-Phe⁷-like immunoreactivities in adult human sympathetic ganglia. *Neuroscience* 1984;12:907–16.
- 35 Hökfelt T, Elfvin LG, Schultzberg M, Goldstein M, Nilsson G. On the occurrence of substance P-containing fibers in sympathetic ganglia: Immunohistochemical evidence. *Brain Res* 1977;132:29–41.
- 36 Matthews MR, Cuello AC. Substance P-immunoreactive peripheral branches of sensory neurons innervate guinea pig sympathetic neurons. *Proc Natl Acad Sci USA* 1982;79:1668–72.
- 37 Konishi S, Tsunoo A, Otsuka M. Substance P and non-cholinergic excitatory synaptic transmission in guinea pig sympathetic ganglia. *Proc J Acad* 1979;55:525–30.